Limited Utility of Quantitative Thresholds on 99mTc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Distinguishing Renal Cell Carcinoma From Oncocytic Renal Masses

Purpose: 99m Tc-sestamibi single-photon emission CT/x-ray CT (SPECT/CT) uses a mitochondria-targeting tracer to differentiate renal cell carcinoma from oncocytomas and hybrid oncocytoma/chromophobe tumors. Initial studies support 99m Tc-sestamibi SPECT/CT’s accuracy, but we previously found that oncocytomas still account for 20% of lesions with low tracer uptake in qualitatively interpreted scans. Here, we assess performance of 99m Tc-sestamibi SPECT/CT utilizing quantitative assessment thresholds, hypothesizing that this may improve test performance. Materials and Methods: All 99m Tc-sestamibi SPECT/CT performed for renal mass evaluation between February 2020 and December 2021 was analyzed. A “hot” mass had qualitatively equivalent or higher 99m Tc-sestamibi uptake than normal renal parenchyma; a “cold” mass did not. Target-to-background ratios (TBRs) were calculated using tracer counts in the masses vs nearby normal parenchyma. Quantitative “hot”/“cold” determinations were made using published TBR cutoffs. Findings were correlated with histology. Results: Seventy-eight patients underwent 99m Tc-sestamibi SPECT/CT for 98 renal masses. For the 52 masses with diagnostic pathology, the negative predictive value (NPV) of qualitatively interpreted 99m Tc-sestamibi SPECT/CT for ruling out oncocytoma was 80%, with a 1.9% false-positive rate. A TBR cutoff of 0.46 achieved the highest NPV of 89.3%, with a 23.1% false-positive rate. A TBR cutoff of 0.74 achieved the lowest false-positive rate of 1.9%, with a 78.3% NPV. No TBR cutoff achieved both higher NPV and lower false positives than the qualitatively interpreted scans. Conclusions: Quantitative TBR cutoffs for interpretation of 99m Tc-sestamibi SPECT/CT scans for renal masses do not offer meaningful improvements in accuracy over qualitative reads. Additional studies are required to better characterize the utility of 99m Tc-sestamibi SPECT/CT in the real-world setting.

Authors

Institutions

Publication Details

Journal
JU Open Plus
Published
2024-09-01
DOI
https://doi.org/10.1097/ju9.0000000000000194
Citations
2
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Limited Utility of Quantitative Thresholds on 99mTc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Distinguishing Renal Cell Carcinoma From Oncocytic Renal Masses

Spencer H. Bell, Jared Schober, Taylor Standiford, Robert Wang et al.
2 citations
JU Open Plus
Renal cell carcinoma treatment
0.84
article

Limited Utility of Quantitative Thresholds on 99mTc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Distinguishing Renal Cell Carcinoma From Oncocytic Renal Masses

Spencer H. Bell, Jared Schober, Taylor Standiford, Robert Wang, Alexander Kutikov, Yi Li, Jian Q. Yu, Mohan Doss
article en
2 citations

Abstract

Purpose: 99m Tc-sestamibi single-photon emission CT/x-ray CT (SPECT/CT) uses a mitochondria-targeting tracer to differentiate renal cell carcinoma from oncocytomas and hybrid oncocytoma/chromophobe tumors. Initial studies support 99m Tc-sestamibi SPECT/CT’s accuracy, but we previously found that oncocytomas still account for 20% of lesions with low tracer uptake in qualitatively interpreted scans. Here, we assess performance of 99m Tc-sestamibi SPECT/CT utilizing quantitative assessment thresholds, hypothesizing that this may improve test performance. Materials and Methods: All 99m Tc-sestamibi SPECT/CT performed for renal mass evaluation between February 2020 and December 2021 was analyzed. A “hot” mass had qualitatively equivalent or higher 99m Tc-sestamibi uptake than normal renal parenchyma; a “cold” mass did not. Target-to-background ratios (TBRs) were calculated using tracer counts in the masses vs nearby normal parenchyma. Quantitative “hot”/“cold” determinations were made using published TBR cutoffs. Findings were correlated with histology. Results: Seventy-eight patients underwent 99m Tc-sestamibi SPECT/CT for 98 renal masses. For the 52 masses with diagnostic pathology, the negative predictive value (NPV) of qualitatively interpreted 99m Tc-sestamibi SPECT/CT for ruling out oncocytoma was 80%, with a 1.9% false-positive rate. A TBR cutoff of 0.46 achieved the highest NPV of 89.3%, with a 23.1% false-positive rate. A TBR cutoff of 0.74 achieved the lowest false-positive rate of 1.9%, with a 78.3% NPV. No TBR cutoff achieved both higher NPV and lower false positives than the qualitatively interpreted scans. Conclusions: Quantitative TBR cutoffs for interpretation of 99m Tc-sestamibi SPECT/CT scans for renal masses do not offer meaningful improvements in accuracy over qualitative reads. Additional studies are required to better characterize the utility of 99m Tc-sestamibi SPECT/CT in the real-world setting.

JU Open PlusVol. 2(9)
Fox Chase Cancer Center (US)
Openalex Percentile: Top 24%
Renal cell carcinoma treatment
0.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.